Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03415126
Other study ID # ASN007-101
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date January 19, 2018
Est. completion date June 30, 2020

Study information

Verified date July 2020
Source Asana BioSciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups. The second part of the study will test how well ASN007 can control cancer.


Description:

Part A is a dose escalation study to determine a safe and tolerable dose of ASN007 for patients with advanced solid tumors. Part A will also describe how the body works on ASN007(pharmacokinetics) and the effects of ASN007 on the body (pharmacodynamics) of ASN007, through blood sampling and optional biopsies..

Part B of the study will enroll patients with particular tumor types and genetic mutations for treatment at the Recommended Phase 2 Dose. Part B will enroll patients in five groups of fifteen patients each:

Group 1: Patients with metastatic BRAF mutated melanoma Group 2: Patients with metastatic NRAS and HRAS mutated solid tumors Group 3: Patients with metastatic KRAS mutated colorectal cancer (CRC) Group 4: Patients with metastatic KRAS mutated non-small cell lung cancer (NSCLC) Group 5: Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) Patients with melanoma will be required to have pre-dose and post-dose biopsies.

Group 6: Patients with metastatic MEK1, BRAF V600E, non-BRAF V600E solid tumors or BRAF fusions without prior treatment with BRAF, MEK, ERK inhibitors


Recruitment information / eligibility

Status Completed
Enrollment 49
Est. completion date June 30, 2020
Est. primary completion date June 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Written informed consent obtained prior to any study-related procedure being performed;

- Male or non-pregnant, non-lactating female patient at least 18 years of age at the time of consent;

- Eastern Cooperative Oncology Group Performance Status 0-1 (Part A) and PS 0-2 (Part B)

- Histologically or cytologically confirmed

- advanced or metastatic solid tumor (Part A)

- Group 1: BRAF mutant melanoma (Part B)

- Group 2: NRAS or HRAS mutant solid tumors(Part B)

- Group 3: KRAS mutant CRC.(Part B)

- Group 4: KRAS mutant NSCLC (Part B)

- Group 5: Pancreatic Ductal Adenocarcinoma (Part B)

- Progressive disease after failure of or intolerant to all available standard systemic treatments that have shown a documented benefit in overall survival for their respective tumor type.

- Measurable or evaluable disease per RECIST v1.1

- Screening hematology values of the following:

- absolute neutrophil count = 1000/µL,

- platelets = 100,000/µL,

- hemoglobin = 9 g/dL

- Screening chemistry values of the following:

- alanine aminotransferase (ALT) and aspartate transaminase (AST) = 3.0 × upper limit of the normal (ULN),

- total bilirubin = 1.5 × ULN,

- creatinine = 1.5 × ULN,,

- albumin = 2.8 g/dL.

- Screening heart function lab test

- creatinine kinase - MB, troponin-I, and troponin-T within normal limits

- Subject is willing and able to comply with all protocol required visits and assessments, including biopsy if assigned.

Exclusion Criteria:

- Prior treatment with ASN007 or another ERK1/2 inhibitor

- Known hypersensitivity to ASN007 or its excipients;

- Part B: Prior treatment with a RAF or MEK pathway inhibitor, except BRAFmutant melanoma (Group 1)

- Prior chemotherapy, targeted therapy or monoclonal antibody therapy within 3 weeks of start of study treatment (Day1), or 5 half-lives, whichever is shorter.

- Concurrent or prior bone marrow factors (e.g. G-CSF, GM-CSF or erythropoietin) within 3 weeks prior to Day 1 of treatment.

- Febrile neutropenia or serious persistent infection within 2 weeks prior to Day 1 of treatment

- Failure to recover from major surgery or traumatic injury within 4 weeks or minor surgery within 2 weeks prior to Day 1 of treatment.

- History of or current evidence / risk of retinal vein occlusion (RVO) central serous retinopathy (CSR), or glaucoma with intraocular pressures = 21 mmHg or other pre-existing ocular conditions that may put the patient at risk for ocular toxicities

- Known central nervous system (CNS) primary tumor, CNS metastases or carcinomatous meningitis (Part A). Patients may be enrolled with CNS metastasis in certain circumstances in Part B.

- Clinically significant heart disorders including an ejection fraction of < 50%

- Other serious uncontrolled conditions such as fungal, bacterial or viral infection; HIV, Hepatitis B or C, bleeding disorders, interstitial lung disease,

- Any other condition that might place the patient at undue risk.

Study Design


Related Conditions & MeSH terms

  • Adenocarcinoma
  • Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Colon Cancer
  • Colon Cancer Liver Metastasis
  • Colonic Neoplasms
  • Lung Neoplasms
  • Malignancy
  • Metastatic Cancer
  • Metastatic Colon Cancer
  • Metastatic Lung Cancer
  • Metastatic Melanoma
  • Metastatic Nonsmall Cell Lung Cancer
  • Metastatic Pancreatic Cancer
  • Neoplasia
  • Neoplasm
  • Neoplasm Metastasis
  • Neoplasms
  • Non Small Cell Lung Cancer Metastatic
  • Pancreas Adenocarcinoma
  • Pancreas Cancer
  • Pancreas Neoplasm
  • Pancreatic Cancer
  • Pancreatic Neoplasms

Intervention

Drug:
ASN007: ascending doses
Oral drug for the treatment of advanced solid tumors
ASN007 RD
Oral drug for the treatment of advanced solid tumors

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts
United States MD Anderson Cancer Center Houston Texas
United States NEXT Oncology San Antonio Texas
United States South Texas Accelerated Research Therapeutics San Antonio Texas
United States H. Lee Moffitt Cancer Center Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
Asana BioSciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other To evaluate the change from baseline in the intensity of phosphorylated ribosomal S6 kinase (RSK) found in tumor biopsies. Evaluate the effect of ASN007 on biomarkers Through the study, average 6 months
Other Evaluate the change from baseline in the amount of circulating tumor DNA Evaluate the effect of ASN007 on biomarkers Every 8 weeks for the first 24 weeks, then every 12 weeks for up to 1 year
Primary Part A: Determine the maximum tolerated dose (MTD) of ASN007 The MTD will be determined by evaluating the number of subjects with treatment related dose limiting toxicity. This is the primary endpoint of Part A First 21 days
Primary Part B: evaluate the overall response rate (number of Complete Responses + Partial Responses) in subjects receiving ASN007 for the treatment of metastatic melanoma, CRC, NSCLC, or pancreatic cancer. This is the primary endpoint for Part B. First 6 months
Secondary Calculate the pharmacokinetic area under the plasma concentration (AUC) of ASN007 Calculate the amount of ASN007 in the bloodstream First 21 days
Secondary Calculate the maximum plasma concentration (Cmax) at steady state. Calculate the maximum amount of ASN007 in the bloodstream First 21 days
Secondary Calculate the terminal elimination rate (T 1/2). Calculate how fast ASN007 leaves the body First 21 days
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients